September 8, 2020 News by Joana Carvalho, PhD Bafiertam, Oral Relapsing MS Therapy, Arrives in US Bafiertam (monomethyl fumarate), a bioequivalent of TecfideraĀ to treat relapsing forms of multiple sclerosis (MS), is now available to patients in the U.S. through a network of specialty pharmacies, Banner Life Sciences, the therapyās developer, announced. Banner previously stated that Bafiertam would arrive on the market…
July 20, 2020 News by Forest Ray PhD Bafiertam, for Adults With Relapsing MS, Available in US in September Banner Life Sciences announced thatĀ Bafiertam (monomethyl fumarate) will become available to adults with relapsing forms of multiple sclerosis (MS) in the United States beginning in September. The U.S. Food and Drug AdministrationĀ (FDA)Ā approved Bafiertam in April as a bioequivalent to BiogenāsĀ Tecfidera…
May 5, 2020 News by Steve Bryson, PhD FDA Approves Bafiertam, Tecfidera Bioequivalent, for Relapsing MS The U.S. Food and Drug Administration (FDA) has given final approval toĀ Banner Life Sciencesā Bafiertam (monomethyl fumarate),Ā a bioequivalent alternative to Biogenās Tecfidera (dimethyl fumarate) to treat people with relapsing…
April 23, 2020 News by InĆŖs Martins, PhD VTS-Aspirin Combos to Ease Flush in RRMS Named Orphan Drug by FDA The U.S. Food and Drug Administration (FDA) has granted orphan drug status to combinations of VTS-Aspirin plus fumarate therapy usingĀ Vumerity (diroximel fumarate) or Bafiertam (monomethyl fumarate) for easing flush in patients with relapsing-remitting multiple sclerosisĀ (RRMS). In the U.S., orphan drug designation is given to…
July 25, 2019 News by Steve Bryson, PhD Tecfidera Up Against Bafiertam in Phase 1 Study of GI Tolerability A first healthy volunteer has enrolled in a randomized, double-blind Phase 1 study to compare the gastrointestinal (GI) tolerability and safety of oral Tecfidera to Bafiertam, an oralĀ bioequivalent in treating relapsing forms of multiple sclerosis (MS),Ā Banner Life Sciences…
January 4, 2019 News by Alberto Molano, PhD Bafiertam, a Bioequivalent of Tecfidera, Receives Tentative OK from FDA for RRMS Banner Life SciencesĀ has received tentative approval from the U.S. Food and Drug Administration (FDA) for its new drug application (NDA) for Bafiertam (monomethyl fumarate), a novel bioequivalent of Biogenās Tecfidera (dimethyl fumarate) for the treatment of relapsing-remitting multiple sclerosis (RRMS). Final approval is expected no later than…